Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Herrlinger

Showing results (211-220 of 222) with videos related to

Pageof 23
Sort By:
Journal for Immunotherapy of Cancer|February 20, 2025
Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancerAlice Talpin, Ana Maia, Jean-Marie Carpier, et al.
The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.
Cancers|July 27, 2022
Two Decades of Brain Tumour Imaging with O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich ExperienceAlexander Heinzel, Daniela Dedic, Norbert Galldiks, et al.
Acta Neuropathologica|February 2, 2025
MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade gliomaLea L Friker, Thomas Perwein, Andreas Waha, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419)Caroline Hertler, Jörg Felsberg, Dorothee Gramatzki, et al.
Blood|March 17, 2026
Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) StudyLeon D Kaulen, Lakshmi Nayak, Philipp Karschnia, et al.
Pageof 23

Showing results (211-220 of 222) with videos related to

Sort By:
Pageof 23
Journal for Immunotherapy of Cancer|February 20, 2025
Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancerAlice Talpin, Ana Maia, Jean-Marie Carpier, et al.
The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.
Cancers|July 27, 2022
Two Decades of Brain Tumour Imaging with O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich ExperienceAlexander Heinzel, Daniela Dedic, Norbert Galldiks, et al.
Acta Neuropathologica|February 2, 2025
MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade gliomaLea L Friker, Thomas Perwein, Andreas Waha, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419)Caroline Hertler, Jörg Felsberg, Dorothee Gramatzki, et al.
Blood|March 17, 2026
Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) StudyLeon D Kaulen, Lakshmi Nayak, Philipp Karschnia, et al.
Pageof 23